Percutaneous Coronary Intervention (PCI) Causes

June 26, 2015 –  The following is good news for patients who will need percutaneous coronary intervention (PCI), however, bleeding problems are not completely resolved. But see for yourself. The U.S. Food and Drug Administration just approved Cangrelor (Kengreal), an intravenous antiplatelet …

Cangrelor (Kengreal) a newly approved antiplatelet drug used during PCI heart procedure Read more »

March 17, 2010 – The U.S. Food and Drug Administration (FDA) has added a Boxed Warning to the label for Clopidogrel [Plavix], the anti-blood clotting medication. The Boxed Warning is about patients who do not effectively metabolize the drug (i.e. …

FDA Drug Safety Communication: Reduced effectiveness of Clopidogrel [Plavix] in patients who are poor metabolizers (i.e. carriers of selected CYP2C19 allelic variants) of the drug Read more »

November 17, 2009 – Today, the US Food and Drug Administration (FDA) informed on new data showing that the proton pump inhibitor (PPI) Omeprazole [Prilosec] or [Prilosec OTC] reduces the anti-blood clotting effect of Clopidogrel [Plavix] by almost half when …

Avoid Coadministration of Clopidogrel [Plavix] and Omeprazole [Prilosec] or Esomeprazole [Nexium] Read more »